Keros Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, cardiovascular, and neuromuscular disorders. The company is a leader in understanding the transforming growth factor-beta (TGF-͢) family of proteins, which act as master regulators of red blood cell and platelet production, as well as the growth, repair, and maintenance of skeletal muscle, bone, adipose, and vascular tissues. Keros leverages this scientific expertise to develop protein therapeutics designed to provide disease-modifying benefits. Its lead clinical pipeline includes rinvatercept (KER-065) for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), elritercept (KER-050) for cytopenias (anemia and thrombocytopenia) in myelodysplastic syndromes (MDS) and myelofibrosis, and KER-012 for pulmonary arterial hypertension (PAH).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
In August 2025, Keros announced a strategic realignment to focus its resources on its lead wholly owned clinical program, rinvatercept (KER-065), for neuromuscular diseases. As part of this restructuring, the company discontinued all development of cibotercept (KER-012) across all indications (including pulmonary arterial hypertension, osteoporosis, and chronic heart failure) and reduced its workforce by approximately 45%.
Expected impact: Streamlines operations, reduces cash burn, and extends the company's cash runway into the first half of 2028, allowing Keros to focus execution on rinvatercept.
Keros implemented a $375 million capital return program, which included share purchase agreements with certain stockholders (such as ADAR1 and Pontifax) and a cash tender offer. Additionally, Keros committed to distributing 25% of any net cash proceeds received on or before December 31, 2028, from its global license agreement with Takeda to its stockholders.
Expected impact: Delivers immediate value to stockholders while maintaining the financial flexibility required to advance the clinical pipeline.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Keros transitioned the global development, manufacturing, and commercialization of elritercept (KER-050) to Takeda (excluding mainland China, Hong Kong, and Macau). This partnership significantly de-risks Keros' financial profile by shifting late-stage development costs to Takeda while retaining substantial commercial upside.
Terms: Keros received a $200 million upfront cash payment in February 2025 and is eligible to receive up to $1.1 billion in development, regulatory, and commercial milestones, plus tiered royalties ranging from low double-digits to high teens on net sales. A $10 million milestone was triggered in July 2025 upon the dosing of the first patient in Takeda's Phase 3 RENEW trial.
Collaboration for the design of a Phase 2 clinical trial evaluating rinvatercept (KER-065) in patients with ALS within the Healey ALS MyMatch program.
Terms: Specific financial terms were not publicly disclosed.